← Ablatotech Vitals
Oncology EvidenceDigest

Role of Novel Combination Therapies in Overcoming Resistance to Targeted Therapies in Advanced Solid Tumors

Oncology · EvidenceDigest

Reviewed by the Ablatotech Vitals editorial team
October 2, 2026 · Reviewer: Vitals Editorial Team
Educational use only. This digest is AI-curated commentary reviewed by clinicians. It is not medical advice and not a diagnostic tool, and it never uses patient-identifiable data. Apply independent clinical judgement and consult primary sources and local guidelines.

Novel combination therapies are emerging as promising strategies to overcome resistance to targeted agents in advanced solid tumors. By simultaneously addressing multiple oncogenic pathways or engaging the immune system, these approaches can restore sensitivity and improve clinical outcomes. While early-phase data are encouraging, further validation in larger, randomized trials is needed to define optimal combinations and patient selection criteria.

Clinical bottom line

Novel combination therapies are emerging as promising strategies to overcome resistance to targeted agents in advanced solid tumors. By simultaneously addressing multiple oncogenic pathways or engaging the immune system, these approaches can restore sensitivity and improve clinical outcomes. While early-phase data are encouraging, further validation in larger, randomized trials is needed to define optimal combinations and patient selection criteria.

What the evidence shows

Adesoye et al. (2026) review advances in targeting HER2 across multiple cancer subtypes, highlighting combination regimens that pair HER2-directed therapies with agents targeting parallel pathways or immune checkpoints. These combinations have demonstrated enhanced efficacy in overcoming resistance mechanisms such as receptor heterogeneity and downstream signaling activation.

Nahta and O’Regan (2019) discuss novel therapies designed to circumvent HER2 therapy resistance in breast cancer, including dual HER2 blockade and combinations with PI3K/AKT/mTOR inhibitors. These strategies address compensatory signaling and have shown improved response rates in resistant tumors.

Guidi et al. (2025) summarize the current landscape of bispecific antibodies in hematologic and solid tumors, which simultaneously engage two targets or immune effector cells. Bispecifics offer a unique modality to overcome resistance by redirecting immune responses or blocking multiple oncogenic drivers.

Bheemavarapu et al. (2025) focus on ALK-mutated pediatric high-risk neuroblastoma, describing how integration of ALK inhibitors with other targeted agents or chemotherapy can overcome resistance conferred by secondary mutations and tumor heterogeneity.

Pinho et al. (2019) provide a broader perspective on emerging novel therapies to overcome resistance, emphasizing the importance of understanding tumor evolution and adaptive mechanisms to rationally design combination regimens.

Vergote et al. (2015) introduce vintafolide, a folate receptor-targeted agent, as an example of precision therapy that can be combined with chemotherapy to improve outcomes in folate receptor-positive tumors, illustrating the potential of combining targeted delivery with cytotoxic agents.

Burdach et al. (2023) present molecular precision chemotherapy data supporting combination strategies that integrate genomic profiling to tailor therapy and overcome resistance in diverse solid tumors.

Caveats and uncertainty

Most evidence derives from early-phase or single-arm studies with limited sample sizes and heterogeneous patient populations.

Toxicity profiles of combination regimens can be additive or synergistic, necessitating careful monitoring and dose optimization.

Resistance mechanisms are complex and dynamic; not all patients may benefit from the same combinations.

Biomarker-driven patient selection remains challenging due to tumor heterogeneity and evolving resistance pathways.

Long-term efficacy and survival benefits require confirmation in randomized controlled trials.

How this may change practice

Incorporation of molecular profiling to identify resistance mechanisms will guide rational selection of combination therapies.

Clinicians should consider combination regimens, especially in patients with acquired resistance to standard targeted agents.

Multidisciplinary collaboration and clinical trial enrollment are critical to access novel combinations and generate evidence.

Enhanced toxicity management protocols will be necessary to safely deliver combination therapies.

Ongoing research will refine predictive biomarkers and optimize sequencing of combination strategies to maximize patient benefit.


References

  1. Adesoye T, et al. Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach. Clin Cancer Res 2026;32(3):450-462. DOI:10.1158/1078-0432.CCR-25-1982
  2. Nahta R, et al. Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer. Resistance to Targeted Anti-Cancer Therapeutics 2019;pp. 123-145. DOI:10.1007/978-3-030-21477-7_7
  3. Guidi L, et al. Bispecific Antibodies in Hematologic and Solid Tumors: Current Landscape and Therapeutic Advances. ASCO Educ Book 2025;45:e473-e481. DOI:10.1200/EDBK-25-473148
  4. Bheemavarapu B, et al. Integration of ALK gene mutations and targeted therapies in pediatric high-risk neuroblastoma: advancements in precision oncology. Ann Med Surg 2025;82:104682. DOI:10.1097/MS9.0000000000003697
  5. Pinho AV, et al. Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance to Targeted Anti-Cancer Therapeutics 2019;pp. 101-122. DOI:10.1007/978-3-030-21477-7_8
  6. Vergote I, et al. Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther Adv Med Oncol 2015;7(3):123-132. DOI:10.1177/1758834015584763
  7. Burdach S, et al. Data from Molecular Precision Chemotherapy: Overcoming Resistance to Targeted Therapies? Clin Cancer Res 2023;29(14):e6523. DOI:10.1158/1078-0432.c.6523214.v1

© 2026 Ablatotech, Inc. All rights reserved. Reviewed by the Ablatotech Vitals editorial team